PAVmed Inc.
PAVMNASDAQHealthcare● Active
$5.18
$-0.27(-4.95%)
Market Cap$2781852
P/E Ratio—
52W High$28.44
52W Low$5.1
PAVmed Inc. (PAVM) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
PAVM · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 15, 2026EPS Actual
-$4.42
Est. -$0.69 · -540.6%
Revenue
$0.00B
Est. $0.00B · -70.3%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 15, 2026
After Market Close
▼ Miss EPS▼ Miss Revenue
PAVM reports quarterly as a NASDAQ-listed Medical - Devices company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.09
Rev. $41.31B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.09
Rev. Est.$41.31B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 13, 2026 | -$0.69 | — | — | — | $0.00B | — |
| ▼ Q2 FY2026 | May 15, 2026 | -$0.69 | -$4.42 | -540.6% | $0.00B | $0.00B | -70.3% |
| ▲ Q1 FY2026 | Mar 26, 2026 | -$4.50 | -$2.05 | +54.4% | $0.00B | $0.00B | +108.0% |
| ▼ Q4 FY2025 | Nov 13, 2025 | -$6.01 | -$8.41 | -39.9% | $0.00B | $0.00B | -60.0% |
| ▲ Q3 FY2025 | Aug 14, 2025 | -$0.25 | -$0.05 | +80.0% | $0.00B | $0.00B | -40.0% |
| ▲ Q2 FY2025 | May 15, 2025 | -$0.29 | -$0.07 | +75.9% | $0.00B | $0.00B | -20.0% |
| ▲ Q1 FY2025 | Mar 25, 2025 | -$0.40 | -$0.06 | +85.0% | $0.00B | $0.00B | -52.4% |
| ▲ Q4 FY2024 | Nov 13, 2024 | -$1.30 | -$0.54 | +58.5% | $0.00B | $0.00B | +4880.0% |
Q3 FY2026
Aug 13, 2026
EPS Actual
—
EPS Est.
-$0.69
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 15, 2026Miss
EPS Actual
-$4.42
EPS Est.
-$0.69
EPS Surpr.
-540.6%
Revenue
$0.00B
Q1 FY2026
Mar 26, 2026Beat
EPS Actual
-$2.05
EPS Est.
-$4.50
EPS Surpr.
+54.4%
Revenue
$0.00B
Q4 FY2025
Nov 13, 2025Miss
EPS Actual
-$8.41
EPS Est.
-$6.01
EPS Surpr.
-39.9%
Revenue
$0.00B
Q3 FY2025
Aug 14, 2025Beat
EPS Actual
-$0.05
EPS Est.
-$0.25
EPS Surpr.
+80.0%
Revenue
$0.00B
Q2 FY2025
May 15, 2025Beat
EPS Actual
-$0.07
EPS Est.
-$0.29
EPS Surpr.
+75.9%
Revenue
$0.00B
Q1 FY2025
Mar 25, 2025Beat
EPS Actual
-$0.06
EPS Est.
-$0.40
EPS Surpr.
+85.0%
Revenue
$0.00B
Q4 FY2024
Nov 13, 2024Beat
EPS Actual
-$0.54
EPS Est.
-$1.30
EPS Surpr.
+58.5%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.00 | $0.00 | $0.00 | 0 |
| Q3 FY2027 | $0.00 | $0.00 | $0.00 | 0 |
| Q2 FY2027 | $0.00 | $0.00 | $0.00 | 0 |
| Q1 FY2027 | $0.00 | $0.00 | $0.00 | 0 |
| Q4 FY2026 | $-0.55 | $-0.55 | $-0.55 | 1 |
| Q3 FY2026 | $-0.58 | $-0.58 | $-0.58 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 15, 2026 | -540.6% | $6.45 | $6.53 | +1.24% |
| ▲ Q1 FY2026 | Mar 26, 2026 | +54.4% | $9.30 | $8.94 | -3.87% |
| ▼ Q4 FY2025 | Nov 13, 2025 | -39.9% | $11.60 | $10.61 | -8.53% |
| ▲ Q3 FY2025 | Aug 14, 2025 | +80.0% | $13.80 | $13.69 | -0.80% |
| ▲ Q2 FY2025 | May 15, 2025 | +75.9% | $21.90 | $18.90 | -13.70% |
| ▲ Q1 FY2025 | Mar 25, 2025 | +85.0% | $24.00 | $22.79 | -5.04% |
| ▲ Q4 FY2024 | Nov 13, 2024 | +58.5% | $33.60 | $30.60 | -8.93% |
| ▲ Q3 FY2024 | Aug 13, 2024 | +42.1% | $24.00 | $22.20 | -7.50% |
Q2 FY2026+1.24%
Report Date
May 15, 2026
EPS Beat/Miss
-540.6%
Price Before
$6.45
Price After
$6.53
Q1 FY2026-3.87%
Report Date
Mar 26, 2026
EPS Beat/Miss
+54.4%
Price Before
$9.30
Price After
$8.94
Q4 FY2025-8.53%
Report Date
Nov 13, 2025
EPS Beat/Miss
-39.9%
Price Before
$11.60
Price After
$10.61
Q3 FY2025-0.80%
Report Date
Aug 14, 2025
EPS Beat/Miss
+80.0%
Price Before
$13.80
Price After
$13.69
Q2 FY2025-13.70%
Report Date
May 15, 2025
EPS Beat/Miss
+75.9%
Price Before
$21.90
Price After
$18.90
Q1 FY2025-5.04%
Report Date
Mar 25, 2025
EPS Beat/Miss
+85.0%
Price Before
$24.00
Price After
$22.79
Q4 FY2024-8.93%
Report Date
Nov 13, 2024
EPS Beat/Miss
+58.5%
Price Before
$33.60
Price After
$30.60
Q3 FY2024-7.50%
Report Date
Aug 13, 2024
EPS Beat/Miss
+42.1%
Price Before
$24.00
Price After
$22.20
Avg Beat Reaction-6.64%
Avg Miss Reaction-3.64%
Beat Rate6 / 8 quarters
Largest Move-13.70% (Q2 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: PAVM ends December
PAVmed Inc. (PAVM) most recently reported earnings on May 15, 2026 for Q2 FY2026, posting EPS of $-4.42 — missing the analyst consensus of $-0.69 by -540.6%. The next PAVM earnings date is expected around September 1, 2026.
Each quarter, investors track PAVM earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. PAVM revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
PAVM's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
PAVM earnings · 5 questionsPAVmed Inc.'s next earnings report is expected around September 1, 2026. PAVM typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; PAVM historically reports after market close (AMC).
PAVM earnings datewhen is PAVM earningsPAVM next earnings datewhen does PAVM report earningsPAVM earnings calendar
▸ Source: FMP · PAVmed Inc. SEC filings · US GAAP · PAVmed Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026